Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 8/20 | 0.43 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21854280 | 0.85 | CAPN1 (0.52) | DCAF1CTSS | |
| SCHEMBL22897214 | 0.83 | DCAF1 (0.51) | PYGLDCAF1CTSVCTSLCTSS | |
| SCHEMBL22885966 | 0.82 | CTSV (0.48) | PYGLDCAF1CTSVCTSLCTSS | |
| SCHEMBL22896923 | 0.82 | PYGL (0.41) | PYGLDCAF1CTSLCNR1CNR2 | |
| SCHEMBL20027817 | 0.82 | PYGL (0.41) | PYGLDCAF1CTSLCNR1CNR2 | |
| SCHEMBL20027914 | 0.80 | DCAF1 (0.48) | PYGLDCAF1 | |
| SCHEMBL20028606 | 0.80 | PYGL (0.43) | PYGLDCAF1CTSLCNR1CNR2 | |
| SCHEMBL20028717 | 0.80 | DCAF1 (0.50) | PYGLDCAF1CTSVCTSLCTSS | |
| SCHEMBL20027619 | 0.79 | PYGL (0.44) | PYGLDCAF1CTSVCTSLCTSS | |
| SCHEMBL22886468 | 0.79 | PYGL (0.44) | PYGLDCAF1CTSVCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | PYGL 925/4885DCAF1 3091/4885TGFBR1 4117/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | PYGL 668/4885DCAF1 3598/4885TGFBR1 4021/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | PYGL 925/4885DCAF1 3091/4885TGFBR1 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.